市场调查报告书
商品编码
1276418
製药行业机器学习的全球市场规模、份额和行业趋势分析报告:按组件、按部署类型、按组织规模、按地区、展望和预测,2023 年-2029Global Machine Learning in Pharmaceutical Industry Market Size, Share & Industry Trends Analysis Report By Component (Solution and Services), By Deployment Mode (Cloud and On-premise), By Organization size, By Regional Outlook and Forecast, 2023 - 2029 |
预计在预测期内,製药行业的机器学习市场规模将以 34.4% 的复合年增长率增长,到 2029 年将达到 114 亿美元。
机器学习还可以通过支持案例跟进和其他建议来帮助防止再犯。人工智能与电子病历相结合。医生偶尔会使用弹出窗口来解释某些遗传特征如何影响患者的医疗状况,或者新药如何改善患者的健康。医生可以点击弹窗来更好地瞭解疾病并推荐最佳疗程。
这些电子记录不仅节省时间和空间,还能积极帮助医生提出更好的治疗建议,并让他们瞭解手头的细节。一些肺癌高发国家已经开始实施人工智能程序,通过分析 X 光和 CT 扫瞄来检测可疑结节和病变,帮助医生更好地诊断肺癌患者。
COVID-19 的影响分析
COVID-19 对製药行业的机器学习市场产生了积极影响。机器学习的使用有助于推进製药领域的疗法和疫苗。此外,机器学习的使用正在发现有前途的 COVID-19 候选药物。机器学习算法可以筛选来自基因数据库和临床试验的大量数据,以识别可能对病毒有效的化合物。这有助于加快通常需要数年时间的药物发现过程,从而促成许多新型 COVID-19 疗法的早期开发。
市场增长因素
提前预测趋势
运营商正在利用人工智能和机器学习提前数月向用户提供登革热等即将爆发的确切地点、日期和时间。该计划还建议在污染区域周围数百米范围内采取登革热控制措施。通过这种方式,机器学习可以帮助研究人员预测即将发生的流行病何时何地发生,提醒有关当局并告知公众。这种能力有可能挽救大量生命,并有望推动机器学习的采用并为市场带来新的增长机会。
扩大技术在医疗行业的应用
使用电子摘要而不是纸质摘要,患者护理变得更简单、更高效。展望未来,基因组(以及大量共生细菌基因组)和定制疗法的进步将大大增加可用信息量。随着收集到更多的患者数据,可以获得更多的见解。由于机器学习具有降低成本、管理和收集大量患者数据以供未来参考等各种好处,预计在製药行业中越来越多地使用机器学习将推动市场增长。
市场製约
数据不一致
当使用许多数据源时,很难协调所有数据并对数据集执行分析。选择单点解决方案或没有强大数据分析系统的公司必须手动编译分析报告和见解。此类过程非常耗时,并且可能不会产生真正的业务相关见解。因此,预计与数据相关的问题将阻碍製药机器学习市场的扩张。
组件视角
基于组件,製药行业机器学习细分为解决方案和服务。到 2022 年,解决方案部分将在製药行业的机器学习市场中占据最高的收入份额。这是由于製药业在发现和发现新药时产生的大量数据。ML 算法可以处理和分析这些数据,以找到可以指导药物开发决策的模式、关係和见解。製药行业对机器学习解决方案的需求是由使药物研发过程更快、更便宜的愿望推动的。
组织规模展望
根据组织规模,製药机器学习市场分为中小企业和大型企业。2022 年,大型企业部门在製药行业的机器学习市场中占据了最大的收入份额。这涉及到大型製药公司使用机器学习技术来评估来自众多来源的海量数据,例如电子病历、临床试验和遗传信息,以发现潜在的药物靶点,改善患者的治疗效果,并改善患者的预后。因为它可以做出预测并改进临床试验设计。
部署模式展望
製药行业市场的机器学习按部署模式分为云和本地。2022 年,製药行业的机器学习市场由本地部分主导。这是因为本地服务可以比云服务节省资金。由于数据使用和分发是 CPU/GPU 密集型的,因此在公共云中维护按需付费的 ML 流程成本很高。迁移到公共云可能需要更大的数据集,从而增加复杂性和成本。
区域展望
按地区划分,对北美、欧洲、亚太地区和 LAMEA 的製药行业机器学习市场进行了分析。北美地区将在 2022 年以最大的收入份额引领製药行业的机器学习市场。专注于研发的北美製药企业对市场贡献巨大。近年来,市场已经采用机器学习来推动创新、提高生产力并加速药物发现和开发。
The Global Machine Learning in Pharmaceutical Industry Market size is expected to reach $11.4 billion by 2029, rising at a market growth of 34.4% CAGR during the forecast period.
The purpose of machine learning in the pharmaceutical industry is to advance medical knowledge, not to replace a doctor. A physician's whole body of knowledge, which includes everything they acquired in medical school and during their training, in addition to their experience treating patients, is scaled to unprecedented levels by artificial intelligence algorithms.
The ability to obtain and process the vast quantity of data available to doctors-information on new treatments, disease symptoms, drug interactions, and how different patients treated in the same way can have different outcomes-is quickly emerging as a crucial talent. And machine learning makes it possible for them to make inferences from that data and put them into action. For instance, machine learning systems may quickly identify a rare ailment, browse the available treatments, and prescribe by compiling data from many patient visits and thousands of doctors. As a result, time is saved, which leads to increased effectiveness and decreased expenses.
Machine learning can also prevent recidivism by helping to follow up on instances and providing extra recommendations. AI is integrated with electronic medical records. When a doctor uses them irregularly, a pop-up appears explaining how particular genetic features can affect the patient's condition or how a new medication could enhance their health. A doctor can better understand the illness and recommend the best course of treatment by clicking the pop-up.
Not only are these electronic records saving time and space, but they are also actively assisting doctors in formulating better treatment recommendations and educating them on the details in front of them. Some countries with a high lung cancer patient population are beginning to deploy AI programs to help doctors better diagnose lung cancer patients by analyzing X-rays and CT scans and spotting suspicious nodules and lesions.
COVID-19 Impact Analysis
Machine learning in pharmaceutical industry market, was positively affected by the COVID-19. The utilization of machine learning has been instrumental in the advancement of treatments and vaccines within the pharmaceutical sector. In addition, prospective COVID-19 drug candidates have been found due to the use of ML. Machine learning algorithms can sift through huge amounts of data from genetic databases and clinical trials to identify compounds potentially effective against the virus. This has contributed to speeding the drug discovery process, which ordinarily takes years, and has led to the quick development of many novel COVID-19 medications.
Market Growth Factors
Predicting epidemic beforehand
Businesses are utilizing AI and machine learning to provide users with the precise place and date of the upcoming outbreak, like a dengue outbreak, a few months in advance. This program also suggests anti-dengue measures a few hundred meters around the contaminated area. Thus, using machine learning, researchers can foresee the timing and location of impending epidemics, alert the relevant authorities, and inform the general public about it. This capability has the potential to save a significant number of lives, which is expected to increase machine learning's adoption and open up new growth opportunities for the market.
Increasing use of technologies in the medical industry
Patient treatment is made simpler and more productive using electronic summaries instead of paper. Future advances in genomes (and the enormous genomics of the symbiotic bacteria) and tailored therapy will greatly increase the amount of information available. As more patient data is gathered, more insights will become accessible. The increased use of machine learning in the pharmaceutical industry is anticipated to drive market growth due to its various benefits, including cost reduction, management, and the collection of massive patient data for future reference.
Market Restraining Factors
Inconsistency of data
Harmonizing all the data and performing analytics over the data set is challenging when many data sources are used. Companies that choose a point solution or do not have a robust data analytics system must manually compile analytics reports and insights. Such a procedure takes a lot of time and might not produce any insights with practical business relevance. Thus, the issues associated with data are expected to hinder machine learning in pharmaceutical industry market's expansion.
Component Outlook
Based on Component, the machine learning in pharmaceutical industry market is segmented into solution and services. The solution segment held the highest revenue share in the machine learning in pharmaceutical industry market in 2022. This is due to the fact that the pharmaceutical industry produces enormous amounts of data when creating and discovering new medicines. ML algorithms can process and analyze this data to find patterns, connections, and insights that can guide drug development decisions. The demand for machine learning solutions in the pharmaceutical industry is further increased by the desire for quicker and more affordable drug research and development processes.
Organization size Outlook
On the basis Organization size, the machine learning in pharmaceutical industry market is divided into SMEs and large enterprises. The large enterprises segment witnessed the largest revenue share in the machine learning in pharmaceutical industry market in 2022. This is because large pharmaceutical corporations can use machine learning technology to evaluate enormous volumes of data from numerous sources, including electronic health records, clinical trials, and genetic information, to find prospective drug targets, forecast patient outcomes, and improve clinical trial design.
Deployment Mode Outlook
By deployment mode, the machine learning in pharmaceutical industry market is classified into cloud and on-premise. The on-premise segment garnered a prominent revenue share in the machine learning in pharmaceutical industry market in 2022. This is because on-premise services can save more capital than cloud services, as the use and distribution of data can be CPU/GPU intensive, making it expensive to maintain an ML process in a public cloud on a pay-as-you-go basis. The data set might need to be bigger to migrate to the public cloud, adding complexity and cost.
Regional Outlook
Region-wise, the machine learning in pharmaceutical industry market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region led the machine learning in pharmaceutical industry market by generating the maximum revenue share in 2022. With a strong emphasis on R&D, the pharmaceutical business in North America makes a considerable contribution to the market. The market has adopted machine learning in recent years to spur innovation, boost productivity, and quicken medication discovery and development.
The major strategies followed by the market participants are Partnerships. Based on the Analysis presented in the Cardinal matrix; Microsoft Corporation and Google LLC are the forerunners in the Machine Learning in Pharmaceutical Industry Market. Companies such as NVIDIA Corporation, IBM Corporation and Cyclica, Inc. are some of the key innovators in Machine Learning in Pharmaceutical Industry Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Google LLC (Alphabet, Inc.), NVIDIA Corporation, IBM Corporation, Microsoft Corporation, Cyclica, Inc., BioSymetrics Inc., Cloud Pharmaceuticals, Inc., Deep Genomics Incorporated and Atomwise, Inc.
Recent Strategies Deployed in Machine Learning in Pharmaceutical Industry Market
Partnerships, Collaborations and Agreements:
Mar-2023: NVIDIA collaborated with AWS, a US-based provider of the cloud-based web platform. The collaboration focuses on developing infrastructure for training large ML models and developing generative AI applications. This collaboration supports customers to make the best use of accelerated computing and generative AI to further explore opportunities.
Oct-2022: BioSymetrics partnered with Deerfield Management, a US-based healthcare investment firm. The partnership focuses on advancing the development of therapeutics. Additionally, as per the agreement, both companies would work on identifying therapeutic targets through BioSymetrics' database and platform.
Jun-2022: Cyclica partnered with Oncocross, a South Korea-based developer of cancer drugs. The partnership includes the discovery and designing of treatments intended for myelofibrosis.
Feb-2022: BioSymetrics came into partnership with Sema4, a US-based health intelligence company. The partnership focuses on drug discovery based on data to accelerate precision medicine. The companies through this partnership aim to deliver an innovative and differentiated method for drug discovery. Further, Sema4's multi-omic data insights and access enhance BioSymetrics' capabilities to discover treatments intended for people with different diseases.
Feb-2022: Microsoft entered into a partnership with Tata Consultancy Services, an Indian company focusing on providing information technology services and consulting. Under the partnership, Tata Consultancy Services leveraged its software, TCS Intelligent Urban Exchange (IUX) and TCS Customer Intelligence & Insights (CI&I), to enable businesses in providing hyper-personalized customer experiences. CI&I and IUX are supported by artificial intelligence (AI), and machine learning, and assist in real-time data analytics. The CI&I software empowered retailers, banks, insurers, and other businesses to gather insights, predictions, and recommended actions in real time to enhance the satisfaction of customers.
Aug-2021: IBM Corporation came into partnership with Cloudera, an American software company providing enterprise data management systems. Through this partnership, both companies would help enterprises with their AI and Data needs. Additionally, this would allow IBM to let Cloudera reside under the IBM Data Fabric which would enable business access to the right data at a better cost, regardless of the data's storage location.
Sep-2021: Deep Genomics announced a partnership with Mila, an AI institute based in Canada. The partnership agreement allows Deep Genomics to join the AI institute's community and make use of the institute's recruitment activities.
Mar-2021: IBM partnered with Cleveland Clinic, a US-based nonprofit medical center. The partnership involves establishing a discovery accelerator, a joint Cleveland clinic, and an IBM center, with the aim to accelerate the speed of discovery in multiple areas including, single-cell transcriptomics, clinical applications, etc. by using high-performance computing on AI, quantum computing technologies, and hybrid cloud.
Product Launches and Expansions:
Nov-2022: NVIDIA joined hands with Microsoft, a US-based tech giant. The collaboration focuses on developing powerful cloud AI computers. The AI supercomputer would be developed by leveraging, Microsoft's Azure supercomputing infrastructure and NVIDIA's GPUs. Further, this collaboration provides advanced AI infrastructure and software to researchers and companies.
May-2021: Google released Vertex AI, a novel managed machine learning platform that enables developers to more easily deploy and maintain their AI models. Engineers can use Vertex AI to manage video, image, text, and tabular datasets, and develop machine learning pipelines to train and analyze models utilizing Google Cloud algorithms or custom training code. After that, the engineers can install models for online or batch use cases all on scalable managed infrastructure.
Mar-2021: Microsoft released updates to Azure Arc, its service that brought Azure products and management to multiple clouds, edge devices, and data centers with auditing, compliance, and role-based access. Microsoft also made Azure Arc-enabled Kubernetes available. Azure Arc-enabled Machine Learning and Azure Arc-enabled Kubernetes are developed to aid companies to find a balance between enjoying the advantages of the cloud and maintaining apps and maintaining apps and workloads on-premises for regulatory and operational reasons. The new services enable companies to implement Kubernetes clusters and create machine learning models where data lives, as well as handle applications and models from a single dashboard.
Mergers and Acquisitions:
Jul-2021: IBM entered into an agreement to acquire Bluetab Solutions Group, an enterprise software, and technical services company. Through this acquisition, Bluetab would become a strategic part of IBM's data services consulting practice to improve its hybrid cloud and AI strategy.
Market Segments covered in the Report:
By Component
By Deployment Mode
By Organization size
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures
FIG